Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

CDC Admits That the PCR COVID Test Cannot Tell the Difference Between Flu and COVID, Says Use Different Test


The CDC has withdrawn its request for emergency use of the PCR test.

The CDC has even come out and told companies to use other tests:

In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.

They are basically telling doctors to use a test that can tell the difference!

And the date should also be noted.

The CDC withdrew the emergency use of the test in July, after December 31st.

They knew the test didn’t work properly yet still approved its use for 5 more months.

People took to Twitter to rightfully make fun of and complain about the CDC.

It’s appalling at the thought of what people will do for money.

For instance, letting people take tests they know don’t work, or having them get vaccines that may hurt them.

This is not the first time the CDC has done something quietly like this.

It has been known for months that the PCR does not detect COVID properly and there are better tests.

Because of these tests how many “positive” COVID cases were the flu?

The new test is supposed to cover symptomatic and asymptomatic people, according to AACC:

Roche has earned Food and Drug Administration emergency use authorization for the cobas SARS-CoV-2 nucleic acid test for use on the cobas Liat system. According to Roche, this singleplex test is the first real-time reverse transcriptase-polymerase chain reaction test that identifies SARS-CoV-2 infection within 20 minutes, and that is authorized to screen both symptomatic and asymptomatic persons at the point of care. It also offers broad SARS-CoV-2 strain coverage as monitored by Roche’s ongoing variant surveillance program. The cobas Liat system fully automates the testing process and features a simplified workflow that enables healthcare professionals to perform this test with minimal training. The cobas SARS-CoV-2 nucleic acid test is intended for use at a wide range of point-of-care settings, including emergency and primary care settings, physician offices, and other SARS-CoV-2 screening locations. It is also available in markets accepting the CE mark.

This test is probably going to be as efficient as the last.

When will Americans learn they are being duped?


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!